Annual SG&A
$51.79 M
-$8.53 M-14.15%
31 December 2023
Summary:
EyePoint Pharmaceuticals annual selling, general & administrative expenses is currently $51.79 million, with the most recent change of -$8.53 million (-14.15%) on 31 December 2023. During the last 3 years, it has risen by +$5.77 million (+12.54%). EYPT annual SG&A is now -14.15% below its all-time high of $60.32 million, reached on 31 December 2022.EYPT Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$12.99 M
+$194.00 K+1.52%
30 September 2024
Summary:
EyePoint Pharmaceuticals quarterly selling, general & administrative expenses is currently $12.99 million, with the most recent change of +$194.00 thousand (+1.52%) on 30 September 2024. Over the past year, it has increased by +$1.96 million (+17.75%). EYPT quarterly SG&A is now -23.69% below its all-time high of $17.03 million, reached on 31 December 2021.EYPT Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$3.15 B
-$103.57 M-3.40%
30 September 2024
Summary:
EyePoint Pharmaceuticals TTM selling, general & administrative expenses is currently -$3.15 billion, with the most recent change of -$103.57 million (-3.40%) on 30 September 2024. Over the past year, it has dropped by -$3.20 billion (-5846.77%). EYPT TTM SG&A is now -49178.99% below its all-time high of $62.94 million, reached on 30 September 2022.EYPT TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EYPT Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -14.2% | +17.8% | -5846.8% |
| 3 y3 years | +12.5% | -3.3% | -6707.0% |
| 5 y5 years | +203.3% | +7.0% | -8803.5% |
EYPT Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -14.2% | +12.5% | -23.7% | +17.8% | -48.7% | at low |
| 5 y | 5 years | -14.2% | +203.3% | -23.7% | +20.6% | -138.1% | at low |
| alltime | all time | -14.2% | >+9999.0% | -23.7% | +797.4% | <-9999.0% | at low |
EyePoint Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $12.99 M(+1.5%) | $51.33 M(+4.0%) |
| June 2024 | - | $12.80 M(-9.3%) | $49.38 M(-3.0%) |
| Mar 2024 | - | $14.11 M(+23.4%) | $50.92 M(-1.7%) |
| Dec 2023 | $51.79 M(-14.1%) | $11.43 M(+3.6%) | $51.79 M(-5.4%) |
| Sept 2023 | - | $11.04 M(-23.1%) | $54.77 M(-7.1%) |
| June 2023 | - | $14.34 M(-4.2%) | $58.96 M(-1.8%) |
| Mar 2023 | - | $14.98 M(+3.9%) | $60.06 M(-0.4%) |
| Dec 2022 | $60.32 M(+13.7%) | $14.41 M(-5.4%) | $60.32 M(-4.2%) |
| Sept 2022 | - | $15.23 M(-1.4%) | $62.94 M(+2.9%) |
| June 2022 | - | $15.44 M(+1.3%) | $61.14 M(+6.3%) |
| Mar 2022 | - | $15.24 M(-10.5%) | $57.55 M(+8.4%) |
| Dec 2021 | $53.08 M(+15.3%) | $17.03 M(+26.8%) | $53.08 M(+11.4%) |
| Sept 2021 | - | $13.43 M(+13.4%) | $47.64 M(+5.2%) |
| June 2021 | - | $11.84 M(+9.9%) | $45.27 M(+2.2%) |
| Mar 2021 | - | $10.77 M(-7.0%) | $44.31 M(-3.7%) |
| Dec 2020 | $46.02 M(-3.5%) | $11.59 M(+4.7%) | $46.02 M(+0.1%) |
| Sept 2020 | - | $11.06 M(+1.7%) | $45.98 M(-2.3%) |
| June 2020 | - | $10.88 M(-12.8%) | $47.06 M(-2.5%) |
| Mar 2020 | - | $12.48 M(+8.1%) | $48.27 M(+1.2%) |
| Dec 2019 | $47.71 M(+179.4%) | $11.55 M(-4.9%) | $47.71 M(+31.9%) |
| Sept 2019 | - | $12.14 M(+0.4%) | $36.16 M(+13.6%) |
| June 2019 | - | $12.10 M(+1.5%) | $31.83 M(+25.0%) |
| Mar 2019 | - | $11.92 M(+52.7%) | $25.46 M(+39.2%) |
| Dec 2018 | $17.07 M(+30.8%) | - | - |
| Sept 2018 | - | $7.81 M(+36.2%) | $18.29 M(+40.1%) |
| June 2018 | $13.06 M(+16.2%) | $5.73 M(+151.3%) | $13.06 M(+31.2%) |
| Mar 2018 | - | $2.28 M(-7.7%) | $9.95 M(-1.4%) |
| Dec 2017 | - | $2.47 M(-3.9%) | $10.09 M(-4.1%) |
| Sept 2017 | - | $2.57 M(-2.0%) | $10.52 M(-6.3%) |
| June 2017 | $11.23 M(+24.7%) | $2.62 M(+8.2%) | $11.23 M(-0.3%) |
| Mar 2017 | - | $2.43 M(-16.3%) | $11.27 M(+0.7%) |
| Dec 2016 | - | $2.90 M(-11.7%) | $11.19 M(+8.3%) |
| Sept 2016 | - | $3.29 M(+23.7%) | $10.33 M(+14.6%) |
| June 2016 | $9.01 M(+11.9%) | $2.66 M(+13.2%) | $9.01 M(+2.8%) |
| Mar 2016 | - | $2.35 M(+14.8%) | $8.77 M(+3.6%) |
| Dec 2015 | - | $2.04 M(+3.8%) | $8.46 M(+2.1%) |
| Sept 2015 | - | $1.97 M(-18.4%) | $8.29 M(+2.9%) |
| June 2015 | $8.06 M | $2.41 M(+18.1%) | $8.06 M(+5.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2015 | - | $2.04 M(+9.1%) | $7.64 M(+1.3%) |
| Dec 2014 | - | $1.87 M(+7.8%) | $7.55 M(+2.2%) |
| Sept 2014 | - | $1.73 M(-13.3%) | $7.39 M(-1.0%) |
| June 2014 | $7.47 M(+4.2%) | $2.00 M(+2.8%) | $7.47 M(-2.0%) |
| Mar 2014 | - | $1.95 M(+13.7%) | $7.62 M(+2.8%) |
| Dec 2013 | - | $1.71 M(-5.5%) | $7.41 M(+0.7%) |
| Sept 2013 | - | $1.81 M(-15.9%) | $7.36 M(+2.7%) |
| June 2013 | $7.17 M(+4.4%) | $2.15 M(+23.9%) | $7.17 M(+8.4%) |
| Mar 2013 | - | $1.74 M(+4.8%) | $6.62 M(-0.3%) |
| Dec 2012 | - | $1.66 M(+2.3%) | $6.63 M(+3.2%) |
| Sept 2012 | - | $1.62 M(+1.3%) | $6.43 M(-6.4%) |
| June 2012 | $6.87 M(-15.3%) | $1.60 M(-9.0%) | $6.87 M(-7.7%) |
| Mar 2012 | - | $1.76 M(+21.1%) | $7.44 M(-0.1%) |
| Dec 2011 | - | $1.45 M(-29.6%) | $7.45 M(-6.9%) |
| Sept 2011 | - | $2.06 M(-5.1%) | $8.00 M(-1.3%) |
| June 2011 | $8.10 M(+16.3%) | $2.17 M(+23.3%) | $8.10 M(+5.3%) |
| Mar 2011 | - | $1.76 M(-11.9%) | $7.69 M(+0.8%) |
| Dec 2010 | - | $2.00 M(-7.7%) | $7.63 M(+2.5%) |
| Sept 2010 | - | $2.17 M(+23.1%) | $7.45 M(+6.9%) |
| June 2010 | $6.97 M(-20.7%) | $1.76 M(+3.8%) | $6.97 M(+4.7%) |
| Mar 2010 | - | $1.70 M(-6.6%) | $6.65 M(-5.1%) |
| Dec 2009 | - | $1.82 M(+7.6%) | $7.01 M(-6.9%) |
| Sept 2009 | - | $1.69 M(+16.7%) | $7.52 M(-14.4%) |
| June 2009 | $8.79 M(-37.0%) | $1.45 M(-29.4%) | $8.79 M(-30.7%) |
| Mar 2009 | - | $2.05 M(-12.1%) | $12.69 M(-10.5%) |
| Dec 2008 | - | $2.33 M(-21.1%) | $14.18 M(-5.9%) |
| Sept 2008 | - | $2.96 M(-44.6%) | $15.06 M(+8.0%) |
| June 2008 | $13.95 M(+7.5%) | $5.34 M(+50.6%) | $13.95 M(+62.1%) |
| Mar 2008 | - | $3.55 M(+10.2%) | $8.61 M(+70.0%) |
| Dec 2007 | - | $3.22 M(+74.4%) | $5.06 M(-6.2%) |
| Sept 2007 | - | $1.84 M(-48.0%) | $5.40 M(+52.0%) |
| June 2007 | $12.98 M(-18.3%) | - | - |
| Dec 2006 | - | $3.55 M | $3.55 M |
| June 2006 | $15.88 M(+78.9%) | - | - |
| June 2005 | $8.88 M(+454.3%) | - | - |
| June 2004 | $1.60 M(+183.3%) | - | - |
| June 2003 | $565.50 K(+50.0%) | - | - |
| June 2001 | $377.00 K | - | - |
FAQ
- What is EyePoint Pharmaceuticals annual selling, general & administrative expenses?
- What is the all time high annual SG&A for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals annual SG&A year-on-year change?
- What is EyePoint Pharmaceuticals quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals quarterly SG&A year-on-year change?
- What is EyePoint Pharmaceuticals TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals TTM SG&A year-on-year change?
What is EyePoint Pharmaceuticals annual selling, general & administrative expenses?
The current annual SG&A of EYPT is $51.79 M
What is the all time high annual SG&A for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high annual selling, general & administrative expenses is $60.32 M
What is EyePoint Pharmaceuticals annual SG&A year-on-year change?
Over the past year, EYPT annual selling, general & administrative expenses has changed by -$8.53 M (-14.15%)
What is EyePoint Pharmaceuticals quarterly selling, general & administrative expenses?
The current quarterly SG&A of EYPT is $12.99 M
What is the all time high quarterly SG&A for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high quarterly selling, general & administrative expenses is $17.03 M
What is EyePoint Pharmaceuticals quarterly SG&A year-on-year change?
Over the past year, EYPT quarterly selling, general & administrative expenses has changed by +$1.96 M (+17.75%)
What is EyePoint Pharmaceuticals TTM selling, general & administrative expenses?
The current TTM SG&A of EYPT is -$3.15 B
What is the all time high TTM SG&A for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high TTM selling, general & administrative expenses is $62.94 M
What is EyePoint Pharmaceuticals TTM SG&A year-on-year change?
Over the past year, EYPT TTM selling, general & administrative expenses has changed by -$3.20 B (-5846.77%)